BRPI0910702A2 - modified factor ix polypeptides and uses thereof - Google Patents

modified factor ix polypeptides and uses thereof

Info

Publication number
BRPI0910702A2
BRPI0910702A2 BRPI0910702A BRPI0910702A BRPI0910702A2 BR PI0910702 A2 BRPI0910702 A2 BR PI0910702A2 BR PI0910702 A BRPI0910702 A BR PI0910702A BR PI0910702 A BRPI0910702 A BR PI0910702A BR PI0910702 A2 BRPI0910702 A2 BR PI0910702A2
Authority
BR
Brazil
Prior art keywords
polypeptides
modified factor
factor
modified
Prior art date
Application number
BRPI0910702A
Other languages
Portuguese (pt)
Inventor
Alan Brooks
Chandra Patel
John E Murphy
Kornelia Kirchner
Marian Seto
Ulrich Haupts
Uwe Gritzan
Xiaoqiao Jiang
Original Assignee
Bayer Healthcare Llc
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc, Bayer Schering Pharma Ag filed Critical Bayer Healthcare Llc
Publication of BRPI0910702A2 publication Critical patent/BRPI0910702A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
BRPI0910702A 2008-04-16 2009-04-16 modified factor ix polypeptides and uses thereof BRPI0910702A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12456708P 2008-04-16 2008-04-16
US4596108P 2008-04-17 2008-04-17
PCT/US2009/040813 WO2009137254A2 (en) 2008-04-16 2009-04-16 Modified factor ix polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0910702A2 true BRPI0910702A2 (en) 2016-07-05

Family

ID=41265284

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0910702A BRPI0910702A2 (en) 2008-04-16 2009-04-16 modified factor ix polypeptides and uses thereof

Country Status (17)

Country Link
EP (1) EP2288622A4 (en)
JP (1) JP2011517951A (en)
KR (1) KR20110005862A (en)
CN (1) CN102083856A (en)
AU (1) AU2009244633A1 (en)
BR (1) BRPI0910702A2 (en)
CA (1) CA2721683A1 (en)
CO (1) CO6311000A2 (en)
CR (1) CR11737A (en)
DO (1) DOP2010000311A (en)
EC (1) ECSP10010551A (en)
IL (1) IL208718A0 (en)
MX (1) MX2010011345A (en)
RU (1) RU2010146387A (en)
SG (1) SG189790A1 (en)
SV (1) SV2010003704A (en)
WO (1) WO2009137254A2 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2423307A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IV polypeptides and use thereof for treatment
CN104004739A (en) * 2007-10-15 2014-08-27 北卡罗来纳-查佩尔山大学 Human factor IX variants with an extended half life
EP3581650B1 (en) * 2008-09-15 2022-12-28 uniQure biopharma B.V. Factor ix polypeptide mutant, its uses and a method for its production
SG186856A1 (en) 2010-07-09 2013-02-28 Biogen Idec Hemophilia Inc Factor ix polypeptides and methods of use thereof
AU2013204511B2 (en) * 2010-11-03 2016-03-17 Gc Biopharma Corp. Modified factor ix polypeptides and uses thereof
TWI595004B (en) * 2010-11-03 2017-08-11 介控生化科技公司 Modified factor ix polypeptides and uses thereof
LT2717898T (en) 2011-06-10 2019-03-25 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof
EP2737311B1 (en) 2011-07-25 2020-12-02 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
EP2842966B1 (en) * 2012-04-27 2018-08-15 Nihon University Therapeutic agent for epithelial and endothelial injury
EP3970738A1 (en) 2012-07-25 2022-03-23 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
EP2900328A4 (en) 2012-09-25 2016-05-11 Biogen Ma Inc Methods of using fix polypeptides
US10391152B2 (en) 2012-10-18 2019-08-27 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
EP3889173B1 (en) 2013-02-15 2023-07-05 Bioverativ Therapeutics Inc. Optimized factor viii gene
SG10201913874TA (en) 2013-03-15 2020-03-30 Biogen Ma Inc Factor ix polypeptide formulations
WO2015048330A2 (en) 2013-09-25 2015-04-02 Biogen Idec Ma Inc. On-column viral inactivation methods
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
EP4332839A2 (en) 2013-12-06 2024-03-06 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
WO2015095809A1 (en) 2013-12-20 2015-06-25 Biogen Idec Ma Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
BR112016021777A2 (en) 2014-03-24 2017-10-03 Biogen Ma Inc LYOPHILIZED FACTOR IX FORMULATIONS
EP3160478A4 (en) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimized factor ix gene
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
MX2018001497A (en) 2015-08-03 2018-05-15 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods of making and using same.
ES2926585T3 (en) 2016-02-01 2022-10-27 Bioverativ Therapeutics Inc Optimized Factor VIII genes
CN105695616A (en) * 2016-04-22 2016-06-22 王冬国 Analysis marker for diagnosing thyroid cancer and application thereof
MX2019006444A (en) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Methods of treating hemophilic arthropathy using chimeric clotting factors.
BR112019015569A2 (en) 2017-01-31 2020-03-17 Bioverativ Therapeutics Inc. FACTOR IX FUSION PROTEINS AND METHODS FOR THEIR PRODUCTION AND USE
FR3069540B1 (en) 2017-07-28 2019-09-13 Universite Claude Bernard Lyon 1 MODIFIED PROTEIN WITH IMPROVED HALF-LIFE
CA3072334A1 (en) 2017-08-09 2019-02-14 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
BR112020006149A2 (en) 2017-09-27 2020-10-20 Sigilon Therapeutics, Inc. manipulated active cell, implantable element, and pharmaceutical composition.
US20210145889A1 (en) 2018-04-04 2021-05-20 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
CN112203646A (en) 2018-04-04 2021-01-08 西吉隆医疗股份有限公司 Implantable particles and related methods
CN113227385A (en) 2018-08-09 2021-08-06 比奥维拉迪维治疗股份有限公司 Nucleic acid molecules and their use for non-viral gene therapy
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
UY38389A (en) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc IMPLANTABLE DEVICES FOR CELLULAR THERAPY AND RELATED METHODS
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
EP3956456A1 (en) 2019-04-17 2022-02-23 Codiak BioSciences, Inc. Compositions of exosomes and aav
WO2021154414A2 (en) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
AU2022226969A1 (en) 2021-02-24 2023-09-14 Bluehalo Llc System and method for a digitally beamformed phased array feed

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2638643B1 (en) * 1988-11-09 1991-04-12 Transgene Sa DNA SEQUENCE ENCODING HUMAN FACTOR IX OR AN ANALOGUE PROTEIN, EXPRESSION VECTOR, TRANSFORMED CELLS, PROCESS FOR PREPARING FACTOR IX, AND PRODUCTS OBTAINED THEREFROM
WO1999003496A1 (en) * 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
HUP0401534A3 (en) * 2001-09-04 2006-01-30 Merck Patent Gmbh Modified factor ix
EP1617799A2 (en) * 2003-04-09 2006-01-25 Wyeth Hemophilia treatment by inhalation of coagulation factors
AU2004296860B2 (en) * 2003-12-03 2010-04-22 Novo Nordisk A/S Glycopegylated factor IX
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
EP2423307A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IV polypeptides and use thereof for treatment
US7700734B2 (en) * 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof

Also Published As

Publication number Publication date
CA2721683A1 (en) 2009-11-12
EP2288622A4 (en) 2012-04-18
JP2011517951A (en) 2011-06-23
MX2010011345A (en) 2011-02-23
IL208718A0 (en) 2010-12-30
AU2009244633A1 (en) 2009-11-12
ECSP10010551A (en) 2010-11-30
EP2288622A2 (en) 2011-03-02
WO2009137254A2 (en) 2009-11-12
RU2010146387A (en) 2012-05-27
KR20110005862A (en) 2011-01-19
CO6311000A2 (en) 2011-08-22
CN102083856A (en) 2011-06-01
WO2009137254A3 (en) 2010-01-14
DOP2010000311A (en) 2011-02-28
CR11737A (en) 2011-02-07
SV2010003704A (en) 2011-02-21
SG189790A1 (en) 2013-05-31

Similar Documents

Publication Publication Date Title
BRPI0910702A2 (en) modified factor ix polypeptides and uses thereof
BR112012002072A2 (en) modified factor ix polypeptides and uses thereof
BRPI0911060A2 (en) factor vii polypeptides that are modified and uses thereof
BRPI0912198A2 (en) anti-fn14 antibodies and uses thereof
BR112012006501A2 (en) polypeptides and uses thereof
SMT201600335B (en) PROTEINS BINDING HETERODIMERS AND THEIR USES
BRPI0920927A2 (en) azaquinolinone derivatives and uses thereof
BRPI0908906A2 (en) heterocyclic compounds and their uses
BRPI0819909A2 (en) antimesothelin antibodies and their uses
BRPI1009455A2 (en) anti-c40 antibodies and uses thereof
BRPI0916515A2 (en) modified bovine g-csf polypeptide and uses thereof
BRPI0810172A2 (en) MODIFIED Factor VII polypeptides and their uses
BR112012003709A2 (en) heterocyclic compounds and their uses
BRPI0923283A2 (en) therapeutic peptide conjugates and uses thereof
DK3663399T3 (en) Modified factor IX polypeptides and uses thereof
BRPI0907231A2 (en) pyrrolpyrimidines and pyrrolpyridines
BRPI0915142A2 (en) polypeptides, nucleic acid and uses thereof
BRPI0913656A2 (en) radioisotope-labeled anti-cdh3 antibodies and uses thereof
BRPI1011404A2 (en) mutants and their uses
BRPI0914682A2 (en) heteroaryl compounds and uses thereof
BRPI0922708A2 (en) minihepidine peptides and methods of use thereof
BRPI0817312A2 (en) Phageru polynucleotides and polypeptides and uses thereof
BRPI0912225A2 (en) lysosomal targeting peptides and uses thereof
BRPI1009413A2 (en) emulsions and adhesives containing protein and their production and use
BRPI0912480A2 (en) high purity monoalkylthine compounds and uses thereof

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]